Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease
about
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsClinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: diagnostic considerations.Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaSevere demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SDCytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications.Müller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder.The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.New insights, promises and challenges.Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients.Progressive cerebral atrophy in neuromyelitis optica.Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.Role of interleukin-6 in the pathogenesis of neuromyelitis optica
P2860
Q26768649-3F853AB2-3EDA-4D7F-9607-F7F039C3221EQ30676331-E17A0EDC-662C-4C00-9513-B8E194E050D9Q30833332-404AF5D6-1842-4A98-8725-80D3DB9CF873Q33763760-803905B4-BF8E-4681-94EC-2D9F03FCEF91Q34338762-B1C35C1C-C5C9-40A0-A599-991EEB0ED894Q34440538-67130455-A48E-46F3-B556-CB880D6F904CQ36303835-87A186B1-F592-433A-AB71-0F3243E0D802Q37160320-C60B7178-0D53-48CD-A908-02C5348925DCQ38171871-C201FB25-6EAF-4729-9263-8FB850E51AA5Q39201610-A3E7394F-84D6-4A6A-933B-7F12D077EA07Q41189041-97E0027A-E5F9-495B-8B7D-7B515E471F56Q43622498-E797F37F-FCD1-40B9-94A2-EC238042DD17Q48954062-227AD0C5-876A-49AD-8167-A69766D051F5Q52149520-5C5DC0E6-1FD7-41C3-A566-86C1B8F85C46Q53249251-9AC8573B-1617-403A-BF08-24DB35E00171Q56771765-F52B85F6-13ED-4E72-B356-CEF3198A0203
P2860
Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Neuromyelitis optica should be ...... r than a demyelinating disease
@de
Neuromyelitis optica should be ...... r than a demyelinating disease
@en
Neuromyelitis optica should be ...... r than a demyelinating disease
@nl
type
label
Neuromyelitis optica should be ...... r than a demyelinating disease
@de
Neuromyelitis optica should be ...... r than a demyelinating disease
@en
Neuromyelitis optica should be ...... r than a demyelinating disease
@nl
prefLabel
Neuromyelitis optica should be ...... r than a demyelinating disease
@de
Neuromyelitis optica should be ...... r than a demyelinating disease
@en
Neuromyelitis optica should be ...... r than a demyelinating disease
@nl
P2093
P2860
P1476
Neuromyelitis optica should be ...... r than a demyelinating disease
@en
P2093
Chihiro Suzuki
Douglas Sato
Hans Lassmann
Hiroshi Kuroda
Ichiro Nakashima
Juichi Fujimori
Kazuo Fujihara
Koichi Narikawa
Masashi Aoki
Masashi Nakamura
P2860
P356
10.1111/J.1759-1961.2012.00030.X
P577
2012-05-01T00:00:00Z